Medeva gross margins from former Fisons business are 70% in first year, firm reports.
MEDEVA ACHIEVES 70% MARGINS ON FORMER FISONS BUSINESS acquired by Medeva from Rhone-Poulenc Rorer in mid-1996. The 10 products acquired by Medeva as part of its purchase of the former Fisons Rochester, N.Y. plant outperformed the rest of the company's business in terms of margins. The gross margin for all of Medeva's businesses was 65%.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth